Mechanizm dzialania statyn i mozliwosci ich zastosowania w terapii psow

• Autorzy: Glinska K , Nicpon J. , Pawlas M.

Warianty tytułu

EN

Mechanism of action statins and possibilities of their application in dog therapy

• Języki publikacji: PL

Abstrakty

EN

Statins are inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) of the key enzyme in cholesterol biosynthesis. Numerous studies on their effectiveness have demonstrated that statins reduce the total cholesterol and low density lipoprotein (LDL) concentration. The application of statins could be useful in the therapeutic management in hyperlipidemias in which dietary therapy does not bring expected results, as well as for primary hyperlipidemia in dogs and lipid metabolism disorders resulting from other diseases like diabetes.

Słowa kluczowe

PL

dzialania niepozadane; psy; farmakologia; zastosowanie; statyny; leczenie; hiperlipidemia; przeciwwskazania; mechanizm dzialania

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2006
• Tom: 62
• Numer: 03
• Opis fizyczny: s.254-256,bibliogr.

Twórcy

autor

Glinska K

• Akademia Rolnicza, pl.Grunwaldzki 47, 50-366 Wroclaw

autor

Nicpon J.

autor

Pawlas M.

Bibliografia

• 1.Alvarez De Sotomayor M.: Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat. Br. J. Pharmacol. 2000, 6, 1179-1187.
• 2.Bailhache E., Briand F., Nguyen P., Krempf M., Magot T., Ouguerram K.: Metabolism of cholesterol ester of apolipoprotein B100-containing lipoproteins in dogs: evidence for disregarding cholesterol ester transfer. Eur. J. Clin. Invest. 2004, 34, 527-534.
• 3.Black A. E., Hayes R. N., Roth B. D., Woo P., Woolf T. F.: Metabolism and excretion of atorvastatin in rats and dogs. Drug Metab. Dispos. 2000, 27, 916-992.
• 4.Davis M. E., Harrison D. G.: Cracking down on caveolin: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in modulating edothelial cell nitric oxide production. Circulation 2001, 1, 2-4.
• 5.Duggan D. E., Vickers S.: Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab. Rev. 1990, 22, 333-362.
• 6.Duncan C. A., Vyas K. P., Kari P. H., Arison B., Prakash S. R., Ramjit H. G., Pitzenberger S. M., Stokker G., Duggan D. E.: In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab. Dispos. 1990, 18, 476-483.
• 7.Endo A.: The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 1992, 33, 1569-1582.
• 8.Essig M.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Cir. Res. 1998, 7, 683-690.
• 9.Igel M., Sudhop T., Von Bergmann K.: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur. J. Clin. Pharmacol. 2001, 57, 357-364.
• 10.Kwak B.: Statins as a newly recognized type of immunomodulator. Nature Medicine 2000, 6, 1399-1402.
• 11.Kwong L. K., Feingold K. R., Peric-Golia L., Le T., Karkas J. D., Alberts A. W., Wilson D. E.: Intestinal and hepatic cholesterogenesis in hypercholesterolemic dyslipidemia of experimental diabetes in dogs. Diabetes 1991, 40, 1630-1634.
• 12.Sessa W. C.: Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends in Mol. Med. 2001, 5, 189-191.
• 13.Takemoto M., Liao J. K.: Pleiotropic effects of 3-hydroxy-3-methyloglutaryl coenzyme a reductase inhibitors. Arteriosclerosis, Thrombosis&Vascular Biol. 2001, 11, 1712-1719.
• 14.Vaughan C. J.: Statins do more than just lower cholesterol. Lancet 1996, 348, 1079-1082.
• 15.Vickers S., Duncan C. A., Chen I. W., Rosegay A., Duggan D. E.: Metabolic disposition studies of simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 1990, 18, 138-145.
• 16.Weitz-Schmidt G.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nature Med. 2001, 6, 687-692.